Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Buffalo, New York 14263


Purpose:

The purpose of this study is to determine whether interleukin-2 given 3 times weekly for 8 weeks in combination with rituximab is effective and safe when compared to rituximab given alone in the treatment of follicular NHL subjects that have never received rituximab as a treatment and are refractory or relapsed after previous chemotherapy.


Criteria:

Inclusion Criteria: - CD20+ follicular B-cell non-hodgkin’s lymphoma with at least 1 site of measurable disease. - Previous treatment with 1 to 4 prior chemotherapy regimens - ECOG performance status of greater than or equal to 2 - Life expectancy of greater than 18 weeks - Meet safety lab requirements and organ function tests Exclusion Criteria: - Prior treatment with rituximab or IL-2 - Prior radioimmunotherapy including Zevalin or Bexxar - 5 or more prior chemotherapy regimens - Clinically significant cardiac disease, lung dysfunction, autoimmune disease, thyroid disease, active infection, unstable psychiatric condition, or HIV infection. - History of allogenic bone marrow transplant - Female subjects that are pregnant or breast feeding - Immunosuppressive therapy including corticosteroids or investigational agents within 4 weeks prior to the planned start of study treatment


NCT ID:

NCT00100737


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Buffalo, New York 14263
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 18, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.